Author/Authors :
Michael K. Schultz، نويسنده , , Jeffrey T. Cessna، نويسنده , , Tamara L. Anderson، نويسنده , , James A. Ponto، نويسنده , , Neil Petry، نويسنده , , Richard J. Kowalsky، نويسنده , , Matthew R. Palmer، نويسنده , , Uwe F. Beinlich، نويسنده , , William Baker، نويسنده , , George H. Hinkle، نويسنده , , Joseph C. Hung، نويسنده , , Timothy Quinton، نويسنده , , Peter A. Rice، نويسنده , , Chaitanya Divgi، نويسنده , , Jeffrey P. Norenberg، نويسنده ,
Abstract :
A blind performance test was conducted to evaluate dose-calibrator measurements at nuclear pharmacies in the United States (US). Two test-sample geometries were chosen to represent those used for measurements of 90Y-ibritumomab tiuxetan (ZEVALIN®). The radioactivity concentration of test-samples was verified by the US National Institute of Standards and Technology. Forty-five results were reported by 10 participants. Eighty percent of reported values were within the US Pharmacopoeia content standard (±10%) for 90Y-ZEVALIN®. All results were within US Nuclear Regulatory Commission conformance limits (±20%) for defining therapeutic misadministrations.
Keywords :
measurement assurance , 90Yttrium , Radiopharmacy , Dose calibrator , ibritumomab tiuxetan
